Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)- Pipeline Review, H2 2019’, provides in depth analysis on Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Cardiovascular, Ophthalmology, Metabolic Disorders, Respiratory, Gastrointestinal, Hematological Disorders, Infectious Disease, Oncology, Central Nervous System, Dermatology, Genetic Disorders, Genito Urinary System And Sex Hormones, Immunology and Musculoskeletal Disorders under development targeting Soluble Guanylate Cyclase (sGC or EC 4.6.1.2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)

– The report reviews Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics and enlists all their major and minor projects

– The report assesses Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“AntiRadical Therapeutics LLC

Bayer AG

Boehringer Ingelheim International GmbH

Cyclerion Therapeutics Inc

Ebelle Pharmaceuticals Inc

NicOx SA

Novan Inc

Novartis AG

Novoteris LLC

Toa Eiyo Ltd

Topadur Pharma AG”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Soluble Guanylate Cyclase (sGC or EC

4.6.1.2) Overview

Soluble Guanylate Cyclase (sGC or EC

4.6.1.2) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Soluble Guanylate Cyclase (sGC or EC

4.6.1.2) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Soluble Guanylate Cyclase (sGC or EC

4.6.1.2) Companies Involved in Therapeutics Development

Bayer AG

Boehringer Ingelheim GmbH

Ironwood Pharmaceuticals Inc

NicOx SA

Novan Inc

Novartis AG

SynZyme Technologies LLC

Topadur Pharma AG

Soluble Guanylate Cyclase (sGC or EC

4.6.1.2) Drug Profiles

A-8R Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1101042 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1237592 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-546544 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-703704 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydroxyurea Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IW-6463 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IWP-953 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGV-354 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naproxcinod Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCX-429 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCX-470 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCX-667 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCX-667 sustained release Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitric oxide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

olinciguat Drug Profile

Product Description

Mechanism Of Action

R&D Progress

praliciguat Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Q-201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

riociguat Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate sGC for Osteoporosis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Soluble Guanylate Cyclase for Acute Respiratory Distress Syndrome Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Soluble Guanylate Cyclase for Glaucoma Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Soluble Guanylate Cyclase for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate sGC for Liver Diseases Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate sGC for Lung Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOPN-53 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vacno Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vericiguat Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Soluble Guanylate Cyclase (sGC or EC

4.6.1.2) Dormant Products

Soluble Guanylate Cyclase (sGC or EC

4.6.1.2) Discontinued Products

Soluble Guanylate Cyclase (sGC or EC

4.6.1.2) Product Development Milestones

Featured News & Press Releases

Aug 06, 2018: Nicox starts Phase ll trial of NCX 470 against latanoprost

0.005%

Jun 23, 2018: Ironwood Presents Praliciguat Phase IIa Study Data Showing Positive Impact on Metabolic and Cardiovascular Clinical Endpoints at the American Diabetes Association’s 78th Scientific Sessions

Jun 20, 2018: Ironwood Pharmaceuticals to Highlight Clinical and Preclinical Data for Praliciguat at the American Diabetes Association’s 78th Scientific Sessions

Jun 07, 2018: Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disease

May 17, 2018: SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment

May 03, 2018: Nicox announces the presentation of scientific data for NCX 667 at ARVO 2018

Jan 11, 2018: Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference

Dec 21, 2017: Ironwood Pharmaceuticals Initiates Phase II Clinical Trial of sGC Stimulator IW-1701 in Patients with Sickle Cell Disease

Dec 04, 2017: Ironwood Reports Top-line Phase IIa Data for IW-1973 Demonstrating Positive Cardiovascular, Metabolic and Endothelial Effects

Oct 31, 2017: Novoteris Investigator Receives Health Canada Clearance to Start a Phase 2a Clinical Trial of its Thiolanox® Nitric Oxide for the Treatment of Non-Tuberculous Mycobacteria

Oct 24, 2017: Bayer to Present Pulmonary Arterial Hypertension Data at the 2017 Annual Meeting of the American College of Chest Physicians

Jun 29, 2017: Bayer Now Enrolling Patients into a Global Pulmonary Arterial Hypertension Study

Jun 05, 2017: Novoteris Receives FDA and Health Canada Clearance to Start a Phase 2 Clinical Trial of its Thiolanox Nitric Oxide for the Treatment of Cystic Fibrosis

May 19, 2017: Bayer to Present Pulmonary Hypertension Data at the American Thoracic Society 2017 International Conference

May 09, 2017: Nicox announces the presentation of scientific data on NCX 667 at ARVO 2017

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by AntiRadical Therapeutics LLC, H2 2019

Pipeline by Bayer AG, H2 2019

Pipeline by Boehringer Ingelheim International GmbH, H2 2019

Pipeline by Cyclerion Therapeutics Inc, H2 2019

Pipeline by Ebelle Pharmaceuticals Inc, H2 2019

Pipeline by NicOx SA, H2 2019

Pipeline by Novan Inc, H2 2019

Pipeline by Novartis AG, H2 2019

Pipeline by Novoteris LLC, H2 2019

Pipeline by Toa Eiyo Ltd, H2 2019

Pipeline by Topadur Pharma AG, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Dormant Products, H2 2019 (Contd..2), H2 2019

Dormant Products, H2 2019 (Contd..3), H2 2019

Dormant Products, H2 2019 (Contd..4), H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports